[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
The use of immunotherapies in oncology has drastically changed the way of treating cancer, providing innovative and efficient therapeutic solutions.
Currently, tremendous R&D efforts are done in immuno-oncology to discover new targets and develop new drugs.
In that context, the use of relevant and robust assays to predict therapeutic efficiencies has become a key for drug discovery programs.
Oncodesign develops a broad range of solutions to support your drug discovery projects in immuno-oncology.
We can provide solutions on a stand alone basis or through an integrated drug discovery package – from hit identification to candidate selection.
Based on human immune material for in vitro/ex vivo phenotypic assays and on advanced preclinical models – syngeneic or humanized – for in vivo assays, our scientists help you to assess your compound efficiency in routine or customized assays.
Dr Caradec obtained his PhD in Biology in the Oncology field. He joined Oncodesign in 2015 as a Director of Discovery Programs to develop kinase inhibitors up to candidate.
He now also heads the in vitro laboratory of Dijon facility and leads preclinical (vitro/vivo) projects for clients in immune-oncology.